Moss Genomics

Moss Genomics FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Moss Genomics (MOSS.CN) as of Nov 2, 2026 is 45.98 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 26.95 % — a change of 70.66% (higher).

FCF Conversion

45.98 %

YoY

70.66%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Moss Genomics is 2025 45.98 % . FCF Conversion Rate (FCF/EBITDA) of Moss Genomics was 2024 26.95 % . It decreases by 70.66% higher compared to the previous year.

The Moss Genomics FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2020
12.50 CAD
Jan 1, 2021
1.57 CAD
Jan 1, 2022
94.37 CAD
Jan 1, 2023
97.91 CAD
Jan 1, 2024
26.95 CAD
Jan 1, 2025
45.98 CAD
The Moss Genomics FCF Conversion history
YEARFCF ConversionYoY
45.98 %+70.66%
26.95 %-72.48%
97.91 %+3.75%
94.37 %+5,923.04%
1.57 %-87.47%
12.50 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Moss Genomics Stock analysis

What does Moss Genomics do? Moss Genomics, Inc. generates revenue through personalized health, anti-aging, and wellness offerings guided by genomic, microbiome, and epigenome data. The company sells products like Gut Health Complete, Gut + Mental Health Complete, and Personalized Probiotic Products. Its services include home collection kits for saliva and fecal samples, genomic and gut microbiome sequencing, and health reports with actionable wellness recommendations. The firm targets consumers seeking tailored health solutions, leveraging AI to analyze DNA and gut microbiome data. Moss Genomics Holdings Inc., its wholly owned subsidiary, supports these offerings. The company operates in San Diego, California, and offers a Multi-Omics Database to improve pharma and biotech drug development. This database integrates genomic, microbiome, and epigenome data from its consumer base, providing value to pharmaceutical and biotech partners. Moss Genomics, Inc. focuses on delivering personalized health insights through its consumer genetic testing segment, which complements its broader health and wellness product line. Moss Genomics, Inc. provides home collection kits for sample gathering, followed by sequencing and analysis to produce health reports. These reports guide users toward personalized wellness strategies, driving customer engagement and repeat purchases. The company’s business model combines direct-to-consumer health products with data-driven insights for the pharmaceutical industry, creating dual revenue streams from both individual consumers and corporate clients. Moss Genomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Moss Genomics stock

FCF Conversion Rate (FCF/EBITDA) of Moss Genomics is 45.98 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Moss Genomics changed from 26.95 % to 45.98 %, representing a 70.66% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Moss Genomics since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Moss Genomics with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Moss Genomics

All Key Metrics — Moss Genomics